Teva's Stock Price Surge Against Its Predictable Woes
Teva stock downgraded to neutral by UBS on heels of $85 million opioid settlement - MarketWatch
Teva Pharmaceutical meets forecasts, but 2023 outlook disappoints | Reuters
Teva Pharmaceutical Industries (NYSE:TEVA) shareholders are up 5.9% this past week, but still in the red over the last five years - Simply Wall St News